On November 15, Roche announced the $2 billion acquisition of Jnana's RAPID platform, which will leverage its RAPID chemical proteomics platform to discover novel small molecule drugs
for cancer, tumor, immune-mediated and neurological diseases.
Under the terms of Tuesday's agreement, Roche offered Jnana an advance payment of $50 million
.
The agreement includes multiple recent and future milestone payments valued at more than $2 billion
.
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemical proteomics RAPID platform to discover drugs targeting highly validated, challenging drug targets to treat diseases
with high unmet need.
The company focuses on developing potential "first-in-class" and potential "best-in-class" therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancers
.
The collaboration is expected to accelerate Roche's innovative research and development
in cancer, oncology, immune-mediated and neurological diseases.
It is understood that Roche has made frequent moves in acquisitions in recent years
.
In 2018, Roche completed two major acquisitions in just two months, one for $1.
9 billion for oncology company Flatiron Health and the other for $2.
4 billion for Foundation Medicine
.
In 2019, it intends to acquire Philadelphia-based biotech Spark Therapeutics for nearly $5 billion; In 2021, it acquired GenMark Diagnostics, an American molecular diagnostic company, for 1.
8 billion US dollars (about 11.
7 billion yuan).
.
.
It is worth mentioning that in addition to Roche, many multinational pharmaceutical companies have also launched large-scale acquisitions since this month to expand their product pipelines and enhance their competitiveness
.
For example, on November 8, scientific instrument manufacturer Bruker Corporation announced the acquisition of Inscopix, which will strengthen Bruker's position as a leader in in vivo brain functional imaging technology, using Ultima multiphoton microscopy at the cellular level and preclinical magnetic resonance imaging systems
at the organism level.
On November 1, Johnson & Johnson will spend about $16.
6 billion to acquire artificial heart maker Abiomed (NASDAQ:ABMD) to consolidate its cardiovascular device business
.
Under the terms of the agreement, Johnson & Johnson will acquire all of Abiomed's outstanding shares through an offer for an advance payment of $380.
00 per share in cash, equivalent to approximately $16.
6 billion.
At present, not only multinational pharmaceutical companies, but also domestic pharmaceutical companies also have a strong desire
for mergers and acquisitions/introduction.
On November 14, Yuyue Medical announced that the company plans to purchase part of its real estate in Xuanwu District, Nanjing, Jiangsu Province, from a related party, Jiangsu Yuyue Technology Development Co.
, Ltd.
, with a contract price of 65.
5603 million yuan
.
The related party transaction is based on the company's R&D and business management needs, and the valuation value of a third-party valuation agency is used as the pricing basis, which does not infringe the interests of all shareholders of the company, especially small and medium-sized investors, will not affect the independence of the company, and will not have a significant impact
on the company's current and future financial status and operating results.
In addition, there are many
cases of "buying, buying, buying" by enterprises such as China Biopharmaceutical, Hengrui Pharmaceutical, CSPC Group, Grand Pharmaceutical, and Huadong Pharmaceutical.
However, it is worth noting that the failure of pharmaceutical acquisitions has also begun to occur
.
In early November, Fosun Pharma announced that its holding subsidiary, Fosun Pharma Industrial, Pte.
Ltd.
(hereinafter referred to as "Fosun Pharma Pte.
") THE ACQUISITION OF ONCOCARE MEDICAL PTE.
LTD, SINGAPORE'S LARGEST PRIVATE ONCOLOGY SPECIALIST CENTRE, WILL BE TERMINATED
.
According to public information, the acquisition took
only about 4 months from the official announcement to the termination.
On June 6 this year, Fosun Pharma announced that Fosun Pharma Pte.
intends to make a cash contribution of no more than S$217.
672 million (about 1.
076 billion yuan) to acquire 60% of the equity
of onCOCARE.
On September 18, CXO company Gloria disclosed the announcement of terminating the acquisition of overseas company SNAPDRAGON CHEMISTRY, INC.
(hereinafter referred to as "Snapdragon") due to "regulatory reasons".
.
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
